Acumen Pharmaceuticals, Inc. (ABOS) Earnings
Acumen Pharmaceuticals, Inc. is expected to report next earnings on November 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.43. ABOS has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +10.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $-0.36 | $-0.45 | -25.2% | — | — |
| May 12, 2026 | $-0.40 | $-0.33 | +18.1% | — | — |
| Mar 26, 2026 | $-0.50 | $-0.41 | +18.0% | — | — |
| Nov 12, 2025 | $-0.63 | $-0.44 | +30.2% | — | — |
| Aug 12, 2025 | $-0.54 | $-0.68 | -25.9% | — | — |
| Mar 27, 2025 | $-0.47 | $-0.62 | -31.9% | — | — |
| Aug 13, 2024 | $-0.28 | $-0.34 | -21.4% | — | — |
| Nov 14, 2022 | $-0.27 | $-0.26 | +3.7% | — | — |
| Aug 15, 2022 | $-0.24 | $-0.25 | -4.2% | — | — |
| May 16, 2022 | $-0.17 | $-0.23 | -35.3% | — | — |
| Nov 15, 2021 | $-0.21 | $-0.10 | +52.4% | — | — |
| Aug 16, 2021 | $-4.56 | $-7.91 | -73.5% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 12, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Lead Program: Subronatug (Subronatug) Phase II Altitude AD Trial - Topline readout from the randomized, placebo-controlled Phase II Altitude AD trial for Subronatug, Acumen's lead anti-amyloid beta oligomer monoclonal antibody, remains on track for late 2026. - The trial tests 35mg/kg and 50mg/kg doses of Subronatug versus placebo, designed to detect a statistically significant difference on the primary endpoint (IDRIS) after 18 months of treatment; top-line data will also include key secondary endpoints (CDR-SB), safety data (including ARIA rates), and fluid/imaging biomarker results. - Patient and site engagement remains strong for both the Phase II trial and its 12-month open-label extension. Acumen presented patient experience data from the trial at the 2026 AAIC conference, highlighting the value of direct patient input for measuring meaningful clinical benefit in early Alzheimer's. ### Enhanced Brain Delivery (EBD) Pipeline Program - Acumen nominated two EBD candidates (ACU-301 and ACU-401) in Q2 2026, exercising its option with JCR Pharmaceuticals to advance the program. ACU-301 is a bispecific based on Subronatug, while ACU-401 uses a novel next-generation anti-amyloid beta oligomer antibody. - Preclinical data presented at AAIC showed all three EBD bispecifics achieved greater brain exposure than unmodified antibody; ACU-401 achieved up to 40-fold greater frontal cortex exposure in non-human primates, with preserved oligomer selectivity and a clean safety profile exceeding expectations. - The program targets an IND filing for the lead EBD candidate in mid-2027. ### Corporate Updates - Acumen will host a Virtual Investor Relations Day on September 16, 2026 to review the company's investment thesis ahead of the Altitude AD readout. - Acumen announced a new collaboration with Unlearn AI to utilize digital twin technology, an exploratory tool for individualized disease progression modeling that will be evaluated for potential use in patient selection and trial analysis for future studies.
Guidance
- The topline readout for the Phase II Altitude AD trial remains guided for late 2026, consistent with prior guidance. - The existing cash and marketable securities balance of $110.2 million is expected to fund all current operational and clinical activities into early 2027. - The IND filing for the lead enhanced brain delivery (EBD) candidate remains guided for mid-2027, consistent with prior timelines.
Segment performance
Acumen Pharmaceuticals is a clinical-stage biotech focused on Alzheimer's disease therapeutics, and it does not report multiple product segments with separate revenue as it has no approved commercial products. As of Q2 2026, the company held $110.2 million in cash and marketable securities. Total operating expenses for the quarter were $32.5 million, consisting of $27.8 million in R&D expenses (a decrease year-over-year driven by lower manufacturing, materials, and CRO costs as the Phase II Altitude AD trial enters its final stage) and $4.7 million in G&A expenses (flat year-over-year). The company reported a $32.6 million operating loss and a $32.7 million net loss for Q2 2026.
Risks & headwinds
- Forward-looking statements regarding trial outcomes, pipeline progress, and cash runway are subject to material risks that could cause actual results to differ materially, per standard SEC disclosures. - Success of the Altitude AD trial is not guaranteed, as there is no certainty that Subronatug will meet the trial's primary efficacy endpoint or demonstrate an acceptable benefit-risk profile. - Novel technologies including digital twin modeling and enhanced blood-brain barrier delivery are unproven in clinical development, and may not yield safe or effective product candidates. - There is no guarantee that new exploratory biomarkers or combination strategies will improve trial outcomes or accelerate development timelines.
Analyst Q&A
Q: A competitor recently released blinded interim data for an oligomer-specific Alzheimer's program. What differentiates Acumen's approach and trial design, and what takeaways can be drawn from the competitor's early safety data for Acumen's upcoming readout?
A: The competitor's data is still very early-stage, so few definitive conclusions can be drawn for Acumen's program. Acumen already published robust Phase 1 data for Subronatug in 2023 that confirmed target engagement of amyloid beta oligomers and produced favorable biomarker outcomes that exceeded expectations, which underpins management's confidence in the Phase II Altitude AD trial.
Q: What parameters were optimized when selecting Acumen's two EBD candidates, and how could the next-generation antibody candidate (ACU-401) offer advantages over the bispecific Subronatug candidate (ACU-301)?
A: The development goal for EBD candidates is to achieve efficient blood-brain barrier penetration via JCR's transferrin carrier technology, preserve or improve amyloid beta oligomer selectivity, and support convenient subcutaneous dosing. The candidate selection process evaluated multiple parameters including TFR affinity, valency, and anemia risk to identify candidates that best match the carrier technology to the therapeutic cargo to deliver oligomer-targeting antibodies to the CNS.
Q: Is each dose of Subronatug in Altitude AD independently powered against placebo, and what work is already underway to minimize the gap between Phase II readout and Phase III initiation?
A: Acumen has not disclosed detailed trial powering or analysis plans publicly, and both tested doses have already demonstrated target engagement. Preparatory work including CMC planning and site preparation is already ongoing to minimize delays, with formal regulatory interactions and Phase III design finalization gated by the upcoming Phase II readout; the goal is to move Subronatug into a single pivotal Phase III trial as quickly as possible if the trial is successful.
Q: What is the differentiated safety profile expected for Subronatug compared to already approved anti-amyloid Alzheimer's therapies?
A: Two key differences support expectations of a better safety profile for Subronatug. First, Subronatug selectively targets soluble amyloid beta oligomers rather than amyloid plaques, which is expected to reduce related safety risks. Second, Subronatug is an IgG2 antibody rather than the IgG1 isotype used by all approved anti-amyloid monoclonals, so it has far less Fc effector function that triggers immune system activation, which is expected to reduce the risk of ARIA and other immune-related adverse events.